A Mechanistic Study to Evaluate the Vasodilatory Effects of AZD3427
Research type
Research Study
Full title
A Mechanistic Study to Evaluate the Vasodilatory Effects of AZD3427 in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) and Patients with Heart Failure with Reduced Ejection Fraction (HFrEF)
IRAS ID
297467
Contact name
Catherine Carter
Contact email
Sponsor organisation
AstraZeneca AB
Eudract number
2020-006045-20
Duration of Study in the UK
0 years, 5 months, 0 days
Research summary
Research Summary
This study is being done to learn more about an experimental drug called AZD3427 and how it might work to help patients with heart failure. Heart failure means that the heart is unable to pump enough blood to support the needs of the body. Heart failure can occur because the heart isn’t contracting and squeezing well or because it’s too rigid and not relaxing well.\nDue to the different causes of heart failure, patients can respond differently to the same treatments. Although other treatments are available and approved for use in heart failure, they are not always effective in some types of heart failure. \nParticipants with heart failure may be invited to take part in this study. \nParticipants will be in the study for up to 99 days, including\n-\tA screening period from 1 to 42 days\n-\tA single-day treatment period \n-\tA follow-up period of 49 to 56 days\nAZD3427 will be given to participants via a needle in their arm (intra-arterial infusion) and the effect of the AZD3427 on the blood flow in their arm will be measured. This will provide information about how AZD3427 works in the body and how it may be beneficial as a treatment for heart failure.\nThe following tests and procedures will be included: Collection of demographics (ages, gender, race), physical examination, weight and height measurements, blood and urine samples, echocardiography (an image of the heart), electrocardiography (a measure of the electrical activity in the heart), pregnancy test (if applicable), assessment of side effects and an assessment of the blood flow in the arms. The study will involve 2 sites in the UK and hopes to enrol approximately 16 participants.Summary of Results
The study did not start and no sites were initiated. Therefore No summary can be provided as the study never started.REC name
East of England - Cambridge East Research Ethics Committee
REC reference
21/EE/0134
Date of REC Opinion
29 Jun 2021
REC opinion
Further Information Favourable Opinion